Michael R. Loken
About
Michael R. Loken is a scholar working on Hematology, Molecular Biology and Immunology.
According to data from OpenAlex, Michael R. Loken has authored 218 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Hematology, 76 papers in Molecular Biology and 63 papers in Immunology. Recurrent topics in Michael R. Loken's work include Acute Myeloid Leukemia Research (103 papers), Hematopoietic Stem Cell Transplantation (42 papers) and Monoclonal and Polyclonal Antibodies Research (31 papers). Michael R. Loken is often cited by papers focused on Acute Myeloid Leukemia Research (103 papers), Hematopoietic Stem Cell Transplantation (42 papers) and Monoclonal and Polyclonal Antibodies Research (31 papers). Michael R. Loken collaborates with scholars based in United States, Canada and Germany. Michael R. Loken's co-authors include Leon W.M.M. Terstappen, Leonard A. Herzenberg, Frank W. Fitch, Deno P. Dialynas, Denise A. Wells, Katherine A. Wall, H. Joachim Deeg, Curt I. Civin, Irwin D. Bernstein and Frederick R. Appelbaum and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.
In The Last Decade
Michael R. Loken
212 papers receiving 9.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael R. Loken United States | 52 | 4.5k | 3.4k | 2.8k | 1.6k | 1.5k | 218 | 9.6k | ||
| Masao Tomonaga Japan | 50 | 2.5k 0.5× | 5.1k 1.5× | 2.2k 0.8× | 1.9k 1.2× | 789 0.5× | 288 | 10.4k | ||
| Robert F. Todd United States | 58 | 2.3k 0.5× | 4.3k 1.3× | 2.8k 1.0× | 1.0k 0.7× | 1.4k 0.9× | 156 | 11.0k | ||
| Peter Vandenberghe Belgium | 58 | 2.3k 0.5× | 2.7k 0.8× | 3.1k 1.1× | 2.2k 1.4× | 986 0.6× | 229 | 10.7k | ||
| Tucker W. LeBien United States | 45 | 2.1k 0.5× | 3.5k 1.0× | 2.1k 0.7× | 1.4k 0.9× | 1.2k 0.8× | 139 | 7.6k | ||
| Alberto Órfão Spain | 66 | 5.4k 1.2× | 5.8k 1.7× | 4.5k 1.6× | 3.1k 2.0× | 587 0.4× | 463 | 16.1k | ||
| E. A. McCulloch Canada | 58 | 7.5k 1.7× | 3.7k 1.1× | 5.8k 2.0× | 3.6k 2.3× | 2.4k 1.5× | 206 | 16.5k | ||
| Bayard D. Clarkson United States | 51 | 3.1k 0.7× | 1.1k 0.3× | 3.3k 1.1× | 2.3k 1.5× | 442 0.3× | 156 | 9.4k | ||
| Neal Flomenberg United States | 58 | 4.0k 0.9× | 4.7k 1.4× | 4.9k 1.7× | 3.0k 1.9× | 436 0.3× | 195 | 13.0k | ||
| Marcos González Spain | 62 | 8.1k 1.8× | 2.5k 0.7× | 5.3k 1.9× | 2.9k 1.9× | 551 0.4× | 376 | 14.1k | ||
| Kenneth A. Foon United States | 44 | 1.5k 0.3× | 3.5k 1.0× | 2.3k 0.8× | 3.5k 2.2× | 2.4k 1.6× | 190 | 10.3k |
Countries citing papers authored by Michael R. Loken
Since
Specialization
Citations
This map shows the geographic impact of Michael R. Loken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Loken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Loken more than expected).
Fields of papers citing papers by Michael R. Loken
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael R. Loken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Loken. The network helps show where Michael R. Loken may publish in the future.
Co-authorship network of co-authors of Michael R. Loken
This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Loken. A scholar is included among the top collaborators of Michael R. Loken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Loken. Michael R. Loken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Huang, Benjamin J., Lauren K. Meyer, Todd A. Alonzo, et al.. (2025). Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 43(17). 1961–1971.
2.
DiPersio, John F., Guenther Koehne, Nirali N. Shah, et al.. (2024). A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 2873–2873.
3.
Stevens, Alexandra M., Kevin E. Fisher, Andrea N. Marcogliese, et al.. (2024). Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children’s Hospital at Baylor College of Medicine. Biomedicines. 12(2). 394–394.
4.
Koehne, Guenther, Benjamin Tomlinson, Hyung C. Suh, et al.. (2023). P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. HemaSphere. 7(S3). e24418bc–e24418bc.
5.
Srivastava, Shivani, Jenny L. Smith, Amanda R. Leonti, et al.. (2021). Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clinical Cancer Research. 27(20). 5718–5730.
6.
Lamble, Adam J., Lisa Eidenschink Brodersen, Todd A. Alonzo, et al.. (2021). CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 40(3). 252–261.
7.
Bolouri, Hamid, Rhonda E. Ries, Laura Pardo, et al.. (2021). A B-cell developmental gene regulatory network is activated in infant AML. PLoS ONE. 16(11). e0259197–e0259197.
8.
Tarlock, Katherine, Todd A. Alonzo, Yi-Cheng Wang, et al.. (2019). Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clinical Cancer Research. 25(16). 5038–5048.
9.
Tarlock, Katherine, Todd A. Alonzo, Michael R. Loken, et al.. (2017). Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 23(14). 3649–3656.
10.
Cooper, Todd M., Rhonda E. Ries, Todd A. Alonzo, et al.. (2017). Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood. 130. 407–407.
11.
Kaeding, Allison, Katherine Tarlock, Sonali P. Barwe, et al.. (2017). Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia. Blood. 130. 2641–2641.
12.
Chauhan, Lata, Todd A. Alonzo, Jim J. Wang, et al.. (2017). Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial. Blood. 130. 2526.
13.
Tarlock, Katherine, Todd A. Alonzo, Robert B. Gerbing, et al.. (2015). Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3 /ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research. 22(8). 1951–1957.
14.
Alonzo, Todd A., Roland B. Walter, Robert B. Gerbing, et al.. (2013). Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy. Clinical Cancer Research. 19(6). 1620–1627.
15.
Georges, George E., Rainer Storb, Peter F. Moore, et al.. (2003). FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease1. Transplantation. 75(7). 933–940.
16.
Sonnenfeld, Gerald, et al.. (1992). Effects of Isolation on Interferon Production and Hematological and Immunological Parameters. Journal of Interferon Research. 12(2). 75–81.
17.
Shah, Virendra O., CI Civin, & Michael R. Loken. (1988). Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis.. The Journal of Immunology. 140(6). 1861–1867.
18.
Loken, Michael R., et al.. (1983). Characterization of Murine Hemopoietic Cells using Rat Anti-Mouse Monoclonal Antibodies. Hybridoma. 2(1). 55–68.
19.
Sarmiento, M, Michael R. Loken, & Frank W. Fitch. (1981). Structural Differences in Cell Surface T25 Polypeptides from Thymocytes and Cloned T Cells. Hybridoma. 1(1). 13–26.
20.
Loken, Michael R., et al.. (1977). Distribution of orally administered bromine-82 in tubercular meningitis: concise communication.. PubMed. 18(2). 123–4.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Masao Tomonaga Breakdown of academic impact, for papers by Robert F. Todd Breakdown of academic impact, for papers by Peter Vandenberghe Breakdown of academic impact, for papers by Tucker W. LeBien Breakdown of academic impact, for papers by Alberto Órfão Breakdown of academic impact, for papers by E. A. McCulloch Breakdown of academic impact, for papers by Bayard D. Clarkson Breakdown of academic impact, for papers by Neal Flomenberg Breakdown of academic impact, for papers by Marcos González Breakdown of academic impact, for papers by Kenneth A. Foon